Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Non-infectious, Non-necrotizing Anterior Scleritis
Interventions
DRUG

Dexamethasone Phosphate Ophthalmic Solution (EGP-437)

Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).

DRUG

Dexamethasone phosphate ophthalmic solution

Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)

Trial Locations (6)

19104

Scheie Eye Institute/University of Pennsylvania, Philadelphia

21287

Wilmer Eye Institute/Johns Hopkins University, Baltimore

Unknown

University of California, San Francisco, San Francisco

University of Miami, Miami

Montefiore Medical Center, The Bronx

Oregon Health & Sciences University, Portland

All Listed Sponsors
lead

John Kempen

OTHER

NCT01059955 - Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study | Biotech Hunter | Biotech Hunter